Integrative genomic analysis of N6-methyladenosine-single nucleotide polymorphisms (m6A-SNPs) associated with breast cancer

• Published in: Bioengineered 2021, Vol.12 (1), p.2389-2397
• Main Authors: Xuan, Zixue, Zhang, Yiwen, Jiang, Jinying, Zheng, Xiaowei, Hu, Xiaoping, Yang, Xiuli, Shao, Yanfei, Zhang, Guobing, Huang, Ping
• Format: Article
• Language: English
• Subjects: Adaptor Proteins, Signal Transducing - genetics; Adenosine - analogs & derivatives; Adenosine - metabolism; Avar; Base Sequence; breast cancer; Breast Neoplasms - genetics; Case-Control Studies; Databases, Genetic; Female; Gene Ontology; Genetic Predisposition to Disease; Genomics; GWAS; Humans; MafF Transcription Factor - genetics; Nuclear Proteins - genetics; Polymorphism, Single Nucleotide - genetics; Quantitative Trait Loci - genetics; Research Paper; single nucleotide polymorphisms (SNPs)
• ISSN: 2165-5979; 2165-5987
• DOI: 10.1080/21655979.2021.1935406

Due to the important role of N6-methyladenosine (m 6 A) in breast cancer, single nucleotide polymorphisms (SNPs) in genes with m 6 A modification may also be involved in breast cancer pathogenesis. In this study, we used a public genome-wide association study dataset to identify m 6 A-SNPs associated with breast cancer and to further explore their potential functions. We found 113 m 6 A-SNPs associated with breast cancer that reached the genome-wide suggestive threshold (5.0E-05), and 86 m 6 A-SNPs had eQTL signals. Only six genes were differentially expressed between controls and breast cancer cases in GEO datasets (GSE15852, GSE115144, and GSE109169), and the SNPs rs4829 and rs9610915 were located next to the m 6 A modification sites in the 3ʹUTRs of TOM1L1 and MAFF, respectively. In addition, we found that polyadenylate-binding protein cytoplasmic 1 might have a potential interaction with rs4829 (TOM1L1) and rs9610915 (MAFF). In summary, these findings indicated that the SNPs rs4829 and rs9610915 are potentially associated with breast cancer because they had eQTL signals, altered gene expression, and were located next to the m 6 A modification sites in the 3ʹUTRs of their coding genes. However, further studies are still needed to clarify how genetic variation affects the epigenetic modification, m 6 A, and its subsequent functions in the pathogenesis of breast cancer.